REDWOOD CITY, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that results from retrospective analyses of a large medical database assessing the use of renin-angiotensin-aldosterone-system inhibitor (RAASi) therapy in patients with chronic kidney disease (CKD) and/or heart failure (HF) will be presented in two posters at the Academy of Managed Care Pharmacy's (AMCP) 27th Annual Meeting and Expo. The two posters examine, respectively, the extent to which patients with CKD and/or HF are receiving guideline-recommended doses of RAASi therapy and potential associations between sub-maximum dosing, cardio-renal events and mortality. In addition, Relypsa is sponsoring a Science & Innovation Theater session at the Meeting to review the latest data in managing cardio-renal patients with hyperkalemia.
Details of the poster presentations and Science & Innovation Theater session are as follows:
Thursday, April 9: 11:45 AM – 2:45 PM PT
- Patients with cardio-renal comorbidities on sub-maximum doses of, or who discontinued, renin-angiotensin-aldosterone system inhibitors manifested worse cardio-renal outcomes than patients on maximum doses of RAASi
(Knispel, et al.; Poster I13)
- Treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors in patients with heart failure (HF) and/or chronic kidney disease (CKD): The role of hyperkalemia.
(Knispel, et al.; Poster N2)
Science & Innovation Theater
Thursday, April 9: 1:30 – 2:00 PM PT
Hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood, is frequently prevalent in patients who suffer from chronic kidney disease, hypertension, diabetes and/or heart failure. Hyperkalemia can lead to life-threatening cardiac arrhythmia and sudden death. Patients with chronic kidney disease and/or heart failure are at particularly high risk for developing hyperkalemia, especially those treated with renin-angiotensin-aldosterone-system (RAAS) inhibitors such as ARBs (Angiotensin Receptor Blockers), AAs (Aldosterone Antagonists), and ACE (Angiotensin-Converting-Enzyme) inhibitors. Although RAAS inhibition has been shown to protect kidney and cardiac function, many patients who could benefit from RAAS inhibitors are untreated or undertreated due to the undesirable side effect of increasing serum potassium.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's two-part pivotal Phase 3 trial of its lead product candidate, Patiromer for Oral Suspension, for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. A New Drug Application for Patiromer for Oral Suspension for the treatment of hyperkalemia was accepted by the U.S. Food and Drug Administration and is currently under review. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.
CONTACT: Alex Dobbin Associate Director, Investor Relations and Corporate Affairs 650.421.9687 IR@relypsa.com